



## FSP 2025 Annual Pathology Conference ACCREDITATION INFORMATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Florida Medical Association designates this live activity for a maximum of *13.25 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CRITERIA FOR SUCCESS

Statements of credit/participation will be awarded based on the participant's attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at [www.flpath.org/claimcme](http://www.flpath.org/claimcme). If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by **February 26, 2025**.

### ACTIVITY FORMAT

Live

### TARGET AUDIENCE

This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.

### STATEMENT OF NEED

The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.

### EDUCATIONAL OBJECTIVES

At the conclusion of this activity, all participants should be able to:

- Recognize molecular immunohistochemistry for the differential diagnosis of a wide range of tumor types
- Discuss the utility and limitations of molecular immunohistochemistry for targeted therapies
- Identify the limitations of conventional immunohistochemistry for soft tissue tumors
- Describe molecular immunohistochemistry for the differential diagnosis of soft tissue tumors
- Discuss the 2023 Bethesda reporting categories, using a case-based approach to highlight differential diagnosis, clues and pitfalls
- Emphasize the importance of integrating clinical, radiologic findings and use of ancillary studies in formulating clinically relevant, and precise diagnostic reports
- Describe the scientific basis behind recent screening and management guideline recommendations around primary HPV screening in the USA



- Discuss the 2019 ASCCP Risk Based Consensus Management Guidelines and the Enduring Consensus Cervical Cancer Screening and Management Guidelines
- Evaluate intraductal and neuroendocrine carcinomas of the prostate for proper diagnosis and reporting
- Describe the role of pathologists in choosing and interpreting genomic tests for prostate cancer
- Recognize common morphological patterns to classify renal tumors
- Review the various types of renal tumors and how to use IHC and molecular tests to diagnose
- Recognize various pathologic and clinical features of Genitourinary tumors
- Appraise unique pathology cases
- Assess pathology knowledge through knowledge-based competition based on American game show

#### **COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS**

All commercial support and educational grants will be communicated to attendees in advance of the meeting.

#### **FACULTY AND PLANNER DISCLOSURES**

##### **PLANNER DISCLOSURES:**

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients except for Dr. Marilyn Bui who disclosed:

- Grant/Research Support:
  - John Cleveland, PhD- Principal Investigator
  - Marusyk, PhD, Phillip Altrock, PhD, David Basanta, PhD- Co-Principal Investigator
  - Robert Gilles, PhD, Bethany Niell, MD, PhD- Co- Principal Investigator
- Consultant/Advisor/Contractor:
  - 2019-2022 Scientific Advisory Board Member of ContextVision AB
  - 2020-Present Scientific Advisory Board Member of Aiforia Technologies Oy
  - 2020-2022 Scientific Advisory Board member of Visiopharm
  - 2020-2022 HER2-Low Pathology Advisory Board Member of AstraZeneca
  - Nov 13, 2020 RNA/GEP Scientific Advisory Board member of Foundation Medicine Institute
  - February-April 2021 Group leader of Advances in the Multidisciplinary Care of Patients with Tenosynovial Giant Cell Tumor on a virtual platform by Spire Learning.
  - July 7, 2021 Lete-cel Regional Steering Committee member of GlaxoSmithKline
  - Nov 7, 2021 Caris Life Sciences Advisory panel meeting
  - March, 26,2022 Sarcoma therapy BioAlas Advisory panel meeting
- Speaker's Bureau:
  - Feb 2, 2021 Merck
  - May 14-15 Osler Review Anatomic Pathology virtual slide review (bone and cytopathology)

*All of the relevant financial relationships listed for this individual have been mitigated (planner and moderator).*

##### **FACULTY DISCLOSURES:**

**Jasreman Dhillon, MD- Has nothing to disclose.**

**Ritu Nayar, MD- Has nothing to disclose.**

**Ming Zhou, MD, PhD- Has nothing to disclose.**

**Shweta Agrawal, MD, FCAP- Has nothing to disclose.**



**Ian Dryden, MD-** Has nothing to disclose.

**Mira Lotfalla, MBBCHD-** Has nothing to disclose.

**Md. Shahrier Amin, MBBS PhD FCAP FRCPC-** Has nothing to disclose.

**Jason L. Hornick, MD, PhD-** *All of the relevant financial relationships listed for this individual have been mitigated.*

**Consultant:** Aadi Biosciences, TRACON Pharmaceuticals, Adaptimmune

**Tricia J. O'Brien-** Has nothing to disclose.

**Marci Crowley, MD-** Has nothing to disclose.

**Sam Amofa-Ho, MD-** Has nothing to disclose.

**Felipe Camacho-Cordovez, MD-** Has nothing to disclose.

**Darby BeDell, MD-** Has nothing to disclose.

**DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION-** It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA's approval of course content for *AMA PRA Category 1 Credits™* does not constitute an endorsement of the ideas, positions or statements contained therein. Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.